Tongji University Researcher Details Findings in Cancer Gene Therapy [Efficacy and safety of recombinant human adenovirus type 5 (H101) combined with immune checkpoint inhibitors (ICIs) in patients with liver metastatic gastric cancer: A...].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article focuses on a study conducted at Tongji University in China, which evaluated the combination of recombinant human adenovirus type 5 (H101) with immune checkpoint inhibitors (ICIs) for treating liver metastatic gastric cancer. The multi-center trial demonstrated a median progression-free survival of 4.8 months and a median overall survival of 13.2 months, with a 33.3 percent objective response rate and a 90.5 percent disease control rate.